Evidence map›Paper›PMID 32714467›Full record

ArticleDisease markers2020

In Vitro and In Vivo Efficacy of DNA Damage Repair Inhibitor Veliparib in Combination with Artesunate against

Y F Li, L M Wen, J Zhao, G D Lv, S Lu, S Lu, X Zheng, B Chen, C Y Tian, Y H Gong and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. In vitro and in vivo Effects of Artesunate onDrug design, development and therapy · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Y F LiPharmaceutical Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.ORCID https://orcid.org/0000-0001-7463-8021
L M WenPharmaceutical Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.ORCID https://orcid.org/0000-0003-3714-4107
J ZhaoPharmaceutical Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
G D LvState Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, Urumqi 830054, China.
S LuDepartment of Orthopedics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.ORCID https://orcid.org/0000-0001-6171-5032
S LuPharmaceutical Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
X ZhengCollege of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi 830054, China.
B ChenPharmaceutical Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
C Y TianCollege of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi 830054, China.
Y H GongPharmaceutical Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
H J GaoPharmaceutical Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
J H WangPharmaceutical Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.ORCID https://orcid.org/0000-0002-8993-3661
Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic echinococcosis (CE), caused by the cestode

Indexed as

Administration, OralAnimalsArtesunateBenzimidazolesCells, CulturedDisease Models, AnimalDNA RepairDose-Response Relationship, DrugDown-RegulationDrug Therapy, CombinationEchinococcosisEchinococcus granulosusFemaleMiceRibosomal ProteinsRibosomal Protein S9ArtesunateBenzimidazolesRibosomal ProteinsRibosomal Protein S9veliparib

Identifiers

PMID32714467
PMCPMC7355356
OpenAlexW3039937805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.